MICHEL ATTAL, MD PhD
University Hosptial toulouse · University Hospital, Toulouse · University Hospital of Toulouse
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name MICHEL ATTAL, MD PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:09 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03679351 · "FU-IFM2009" Database Post IFM/DFCI 2009 StudyUniversity Hospital, Toulouse · unknown · Multiple Myeloma · principal investigator
- Ph3NCT02197221 · Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaUniversity Hospital, Toulouse · completed · Multiple Myeloma · principal investigator
- Ph3NCT01191060 · Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsUniversity Hospital, Toulouse · completed · Myeloma · principal investigator
- Ph2NCT01053949 · IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaUniversity Hospital, Lille · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.